PL3797771T3 - Rebamipid do stosowania w zapobieganiu i leczeniu celiakii - Google Patents

Rebamipid do stosowania w zapobieganiu i leczeniu celiakii

Info

Publication number
PL3797771T3
PL3797771T3 PL19020503T PL19020503T PL3797771T3 PL 3797771 T3 PL3797771 T3 PL 3797771T3 PL 19020503 T PL19020503 T PL 19020503T PL 19020503 T PL19020503 T PL 19020503T PL 3797771 T3 PL3797771 T3 PL 3797771T3
Authority
PL
Poland
Prior art keywords
rebamipide
prophylaxis
treatment
celiac disease
celiac
Prior art date
Application number
PL19020503T
Other languages
English (en)
Original Assignee
Square Power Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Square Power Ltd filed Critical Square Power Ltd
Publication of PL3797771T3 publication Critical patent/PL3797771T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19020503T 2019-09-03 2019-09-03 Rebamipid do stosowania w zapobieganiu i leczeniu celiakii PL3797771T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19020503.9A EP3797771B1 (en) 2019-09-03 2019-09-03 Rebamipide for use in prophylaxis and treatment of celiac disease

Publications (1)

Publication Number Publication Date
PL3797771T3 true PL3797771T3 (pl) 2022-06-27

Family

ID=67874202

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19020503T PL3797771T3 (pl) 2019-09-03 2019-09-03 Rebamipid do stosowania w zapobieganiu i leczeniu celiakii

Country Status (10)

Country Link
US (1) US20220304996A1 (pl)
EP (1) EP3797771B1 (pl)
JP (1) JP7649296B2 (pl)
CN (1) CN114340630B (pl)
BR (1) BR112022003935A2 (pl)
CA (1) CA3153325A1 (pl)
ES (1) ES2913792T3 (pl)
MX (1) MX2022002625A (pl)
PL (1) PL3797771T3 (pl)
WO (1) WO2021043835A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444823B (zh) * 2022-10-12 2024-02-23 苏州中化药品工业有限公司 一种含瑞巴派特颗粒及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1722630A4 (en) * 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
JP2008050324A (ja) 2006-08-28 2008-03-06 Ohara Yakuhin Kogyo Kk 苦味遮蔽組成物。
CN105943534A (zh) * 2008-04-15 2016-09-21 萨可德生物科学公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2012128394A1 (en) * 2011-03-24 2012-09-27 Otsuka Pharmaceutical Co., Ltd. A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide
SA113340675B1 (ar) 2012-06-26 2015-08-16 استيش. كو.، ليمتد أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها
WO2015154010A1 (en) * 2014-04-04 2015-10-08 Perrow Wendy Methods of treating celiac disease with larazotide
CN109562137A (zh) * 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物

Also Published As

Publication number Publication date
ES2913792T3 (es) 2022-06-06
MX2022002625A (es) 2022-06-02
WO2021043835A1 (en) 2021-03-11
EP3797771A1 (en) 2021-03-31
BR112022003935A2 (pt) 2022-05-31
JP7649296B2 (ja) 2025-03-19
CA3153325A1 (en) 2021-03-11
JP2022546120A (ja) 2022-11-02
CN114340630A (zh) 2022-04-12
KR20220062548A (ko) 2022-05-17
US20220304996A1 (en) 2022-09-29
EP3797771B1 (en) 2022-02-23
CN114340630B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
ZA202204809B (en) 5-ht2a agonists for use in treatment of depression
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
EP4066837A4 (en) USE OF BI853520 IN THE TREATMENT OF CANCER
IL287802A (en) Preparations and methods for the treatment of eye diseases
GB202416189D0 (en) Methods for the prophylaxis and treatment of Covid and Covid-19
IL278978A (en) Preparations and methods for treating eczema
IL288787A (en) Methods and preparations to improve results in cancer patients
HUE064596T2 (hu) Menstruációs ciklus által kiváltott tünetek kezelése
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
PL3741370T3 (pl) Rebamipid do zastosowania w profilaktyce synukleinopatii
ZA202207493B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
PL3797771T3 (pl) Rebamipid do stosowania w zapobieganiu i leczeniu celiakii
IL287538A (en) Preparations and methods for the treatment of cancer
ZA202107235B (en) Compositions and methods for treating ocular disease
IL287441A (en) Preparations and methods of use for the treatment of dry eye
ZA202105583B (en) Methods of diagnosing and treating cervical cancer
IL291626A (en) Celiac treatment
IL291235A (en) An object and a dressing for improved healing and methods of use
IL286649A (en) The history of quinoline and its use in cancer treatment
IL288415A (en) Combinations and methods for the treatment of hemochromatosis
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL286836A (en) Combinations of transcription inhibitors and immune checkpoint inhibitors to treat the disease
PL3797772T3 (pl) Rebamipid do zastosowania w zapobieganiu i leczeniu choroby Leśniowskiego-Crohna
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency